Literature DB >> 2504888

Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid.

P Gallo1, M G Piccinno, S Pagni, V Argentiero, B Giometto, F Bozza, B Tavolato.   

Abstract

Serum and cerebrospinal fluid (CSF) levels of interleukin-2 (IL-2), soluble IL-2 receptor (sIL-2R), and gamma-interferon (gamma-IFN) were measured in multiple sclerosis (MS) patients, human immunodeficiency virus type 1 (HIV-1)-infected patients and normal controls (NC). Increased levels of both IL-2 and sIL-2R were found in MS serum. Moreover, 11 of 50 MS patients showed detectable levels of IL-2 in the CSF. HIV-1-infected patients had increased levels of sIL-2R in serum and, less frequently, in the CSF. gamma-IFN was never detected in serum and CSF of all the patients studied. These findings confirm preliminary reports, further stress a systemic T-cell activation in MS, and support the hypothesis that an immunologic disorder exists in such patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504888     DOI: 10.1016/0022-510x(89)90171-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  30 in total

1.  Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups.

Authors:  M Rovaris; D Barnes; N Woodrofe; G H du Boulay; J W Thorpe; A J Thompson; W I McDonald; D H Miller
Journal:  J Neurol       Date:  1996-07       Impact factor: 4.849

2.  Immune-mediated mechanisms in multiple sclerosis.

Authors:  D Fuchs; G Reibnegger; E R Werner; H Wachter
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

3.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

4.  KIR2DL4-HLAG interaction at human NK cell-oligodendrocyte interfaces regulates IFN-γ-mediated effects.

Authors:  P P Banerjee; L Pang; S S Soldan; S M Miah; A Eisenberg; S Maru; A Waldman; E A Smith; Y Rosenberg-Hasson; D Hirschberg; A Smith; D V Ablashi; K S Campbell; J S Orange
Journal:  Mol Immunol       Date:  2018-11-24       Impact factor: 4.407

5.  Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.

Authors:  C E Shaw; P R Dunbar; H A Macaulay; T J Neale
Journal:  J Neurol       Date:  1995-01       Impact factor: 4.849

6.  Impact of a Demyelination-Inducing Central Nervous System Virus on Expression of Demyelination Genes in Type 2 Lymphoid Cells.

Authors:  Satoshi Hirose; Mihoko Kato; Kati Tormanen; Pedram Shafiei Jahani; Omid Akbari; Homayon Ghiasi
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

7.  An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis.

Authors:  P Ferrero; P Rocca; P Benna; C De Leo; E Montalenti; L Ravizza; B Bergamasco
Journal:  Ital J Neurol Sci       Date:  1992-11

8.  Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-02       Impact factor: 10.154

9.  Nerve growth factor (NGF) in cerebrospinal fluid (CSF) from patients with various neurological disorders.

Authors:  A R Massaro; C Soranzo; E Bigon; S Battiston; A Morandi; A Carnevale; L Callegaro
Journal:  Ital J Neurol Sci       Date:  1994-03

10.  IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production.

Authors:  Lisa M Maier; Christopher E Lowe; Jason Cooper; Kate Downes; David E Anderson; Christopher Severson; Pamela M Clark; Brian Healy; Neil Walker; Cristin Aubin; Jorge R Oksenberg; Stephen L Hauser; Alistair Compston; Stephen Sawcer; Philip L De Jager; Linda S Wicker; John A Todd; David A Hafler
Journal:  PLoS Genet       Date:  2009-01-02       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.